Mirion Technologies, Inc. (MIR) Earnings Call Transcript & Summary
February 12, 2025
Earnings Call Speaker Segments
Eric Linn
executiveOkay, thank you Stephanie. Good morning to all of you, and thank you for joining us on this earnings conference call, where we'll be discussing Mirion's results for the fourth quarter as well as the entire 2024 fiscal year. Joining me on the line are Tom Logan, who serves as Mirion's CEO, and Brian Schopfer, Mirion's CFO. Prior to diving into our prepared comments for today, I'd like to caution everyone that forward-looking statements will be part of this call, and the actual results we report might end up differing materially from what those forward-looking statements anticipate. The elements that could lead actual results to diverge are covered in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other filings Mirion makes with the SEC under the Risk Factors heading. Unless we say otherwise, any references to a quarter during today's discussion pertain to the fourth quarter, which concluded on December 31st, 2024. Also, certain financial measures discussed on this call will not be prepared in accordance with generally accepted accounting principles. You can find a reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures in the appendix of the presentation accompanying today's call, alongside a $215 million figure we're highlighting. All earnings materials are accessible in the Investor Relations section of our website, www.mirion.com. With that said, I'll turn things over to Tom, who will begin on slide two.
Tom Logan
executiveEric, thanks, and good morning to all of you. At Mirion, 2024 proved to be a landmark year. It's my pleasure to share that we achieved record results for both the fourth quarter and the full year, with revenue, adjusted EBITDA, and adjusted earnings per share each surpassing prior peaks. I want to extend a huge thank you to the entire Mirion team for these exceptional outcomes. Earnings didn't just increase — their quality improved too, since we lifted the adjusted EBITDA margin by 110 basis points across the full year and pushed adjusted EPS from $0.34 to $0.41 per share for the year, all achieved through deliberate operational and commercial initiatives. Equally important, for a second consecutive year we met our guidance. Even with considerable foreign exchange headwinds, our performance matched or exceeded what we had guided for 2024. We also made major moves in 2024 to strengthen our capital structure; in May, we finished redeeming the outstanding public warrants and repriced our term credit facility. During the fourth quarter, every one of the three tranches of our Founder Shares became fully vested. Consequently, we began 2025 with a far cleaner and simpler capital structure. The strides taken in 2024 are fueling momentum that continues into 2025. First, regarding our current backlog, we kick off 2025 with a solid pipeline of new activity. Roughly 49% of the revenue we expect for 2025 already sits in backlog, a favorable comparison to the 46% coverage we carried into 2024. Outside of backlog, positive momentum in both nuclear power and nuclear medicine — which you've heard us describe across recent quarters — is evident in our book-and-bill flow business. A strong installed base underpins the high degree of recurring revenue our business produces. We're witnessing encouraging movement on the $300-$400 million in new order opportunities that we first discussed on our October earnings call and that I restated at our Investor Day in December. These opportunities remain at an early stage, yet we're happy with our position as of today. Crucially, not a single one of these projects has been lost so far, and more bidding opportunities are emerging. As the year unfolds, discussions are advancing, and we anticipate sharing further details down the road. Second, we're positioned to grow in 2025. Scale is central to how our business model operates, and in 2025 we anticipate making meaningful progress toward the long-range 2028 plan we unveiled at our Investor Day. In addition, a great deal of the self-help work accomplished in 2024, especially around procurement, will show up more clearly in our future results. Third, capital allocation holds our complete attention. We emphasized this at our December Investor Day, and I remain heartened by the strong pipeline of M&A and organic opportunities that lie ahead. Turning back to our Investor Day, the strategy and the opportunities open to Mirion keep drawing favorable responses. A recurring subject in our follow-up conversations is the Category of One spot Mirion holds, which panel four illustrates; for those investing, we represent a compelling way to gain nuclear exposure, something that's hard to find within nuclear instrumentation. Roughly 37% of Mirion's 2024 revenue came out of the commercial nuclear power arena, far above what any of our nearest rivals can claim. Investors in Mirion get cradle-to-grave participation across the 100-year nuclear power lifecycle. Be it the installed base of today, new builds, or decommissioning activity, Mirion's solutions play an essential role in nuclear infrastructure. That statement isn't mere exaggeration. Our conviction is strong that our perspective on the nuclear power market is unlike anyone else's. Right now we observe robust worldwide demand from our installed base, which accounts for over 95% of all commercial reactors in operation globally. Operators are keen to put money into their current reactors so they can extend useful life or boost capacity. On top of that, new construction is underway across the globe now that profitability dynamics have gotten better and the appetite for clean, reliable energy keeps expanding. This nuclear power supertrend is still very much intact, even after the initial worries surrounding DeepSeek a few weeks back. Hyperscalers are pouring money in during 2025 to keep growing capabilities and capacity; projections put their capital spending increase at roughly 44% in 2025, reaching beyond $320 billion, and their spending continues on utility-scale reactors as well as small modular reactors so their future needs are secured. Outside the hyperscalers, news coverage shows ongoing backing and mounting momentum behind nuclear power. A few recent illustrations include the U.K., where the government is anticipated to grant developers greater latitude regarding where new reactors can be built, supporting rising clean energy demand. In France, just as we'd been speculating, EDF intends to ready six sites for new data centers since AI demand is projected to fuel infrastructure investment. Indeed, before a recent AI summit, French President Emmanuel Macron pointed to more than EUR 100 billion in AI projects within the country. Over here in the U.S., President Trump is putting domestic energy sources first, nuclear among them. And South Carolina's governor recently pushed for reviving that state's nuclear energy sector, which includes the previously abandoned V.C. Summer nuclear expansion. The hardware, software, and service solutions we deliver are mission-critical for the customers we serve; we hold the global leader position in 17 of the 19 product categories we offer, owing to a mix of superior quality and service plus a global reach our competitors simply cannot match. Put plainly, we supply compulsory products to customers operating in highly regulated industries where failure carries a high cost. Our customers understand the part we play in their success; we've been increasingly formalizing strategic alliances across both of our operating segments. To illustrate, within our Medical group, we signed a strategic alliance agreement with Siemens Healthineers last year. On the nuclear power side, we signed an MOU with Electronics Corporation of India, a leader in the Indian market, to support the rapid growth of India's nuclear sector. Additionally, during 2024 we entered into a strategic partnership agreement with EDF. The biggest nuclear plant operator globally is France, and for the coming two decades we have become the sole supplier for every one of their new nuclear build efforts. When it comes to concentrating purely on detecting, measuring, and analyzing ionizing radiation, Mirion occupies a Category of One. That phrase isn't merely a slogan. It describes what we mean to the clients we work alongside, the investors whose interests we represent, and the markets we cater to. Moving on now to how the quarter performed, shown on panel five: revenue for the fourth quarter reached $254.3 million, setting a fresh quarterly record. That result mirrors the demand we keep witnessing from nuclear power plants currently in operation. Roughly 80% of our nuclear revenue, based on historical patterns, derives from this installed base. Investments are being made by nuclear reactor operators in their facilities, whether for extending how long they operate or enlarging fleet capacity. Every one of these goals generates revenue possibilities for Mirion. The fourth quarter's results likewise mirror appealing radiopharmaceutical demand. We keep expanding this portion of the business, since therapeutic nuclear medicine is transforming cancer treatment. Furthermore, we are discovering more and more ways to market Nuclear and Safety products to our nuclear medicine clientele. In the past year by itself, we sold over $15 million of equipment that is traditionally industrial to Medical customers, which amounts to a 38% rise. Adjusted EBITDA for the fourth quarter came to almost $70 million. Compared with the identical period a year earlier, adjusted EBITDA rose 14%, while margins grew 90 basis points, propelled by procurement initiatives and operating leverage. This demonstrates robust operating results powered by our business system, which has served as the basis of our operating activities for over 15 years. Adjusted EPS for the fourth quarter stood at $0.17 per share, which is $0.02 better than the fourth quarter of last year. Both the fourth quarter and the entirety of 2024 reflect ongoing solid performance. We are carrying out the strategy presented at our Investor Day in order to take advantage of our distinctive position. We observe considerable market opportunities, spanning organic and inorganic, and our growth drivers continue to be firmly on track. At this point, I'll hand things over to Brian so he can go over the quarterly and full year results.
Brian Schopfer
executiveThanks, Tom, and I appreciate everyone being on the call today. I'm going to walk through the detailed financial results, and I'll start on slide six. For the fourth quarter, enterprise revenue rose 10.4%, reaching $254.3 million, which compares with $230.4 million in the same quarter a year earlier. Organic growth in Q4 came in at a similar 10.3%, since FX headwinds mostly canceled out 0.5% of inorganic growth. The robust organic revenue performance in Q4 is still being powered mainly by roughly 7% growth in nuclear power, a striking 21% increase in nuclear medicine, and 14% growth in dosimetry. It's important to remember that during the fourth quarter of 2023, nuclear power had double-digit growth, which created a really difficult comparison that we managed to grow on top of. For the full year, enterprise revenue increased 7.5% to $860.8 million compared with 2023. Organic growth reached 6.6% in 2024, which exceeded the guidance range of between 5% and 6% that we had narrowed back in October. Keep in mind, we delivered over 9% organic growth in 2023. Within the Nuclear and Safety group, nuclear power activity increased 8.5% for the year, driven largely by momentum from Europe along with safety-critical products supplied to Korea. In the Medical group, nuclear medicine stood out as the largest organic contributor, expanding 7.5% for the year. We achieved double-digit growth in nuclear medicine during every quarter following the first quarter ERP implementation, and we anticipate double-digit growth in 2025 within this end market. Inorganic growth for the enterprise was 1%, which reflects the EC2 acquisition that closed in late 2023, partly offset by the rehab business divestiture. Adjusted EBITDA for Q4 and the full year came to $69.6 million and $203.6 million, respectively; we closed out the year having posted six straight quarters of margin expansion relative to the same periods a year earlier. As I mentioned, 2024 adjusted EBITDA landed at the top end of our December guidance range of between $195 million and $205 million, and it was above the initial guidance we provided at the start of the year. The 2024 adjusted EBITDA margin was 23.7%, which works out to roughly 110 basis points of margin improvement for the year; we continue to make steady progress toward the 2028 30% adjusted EBITDA margin target that we laid out at our December Investor Day. Adjusted earnings per share for the fourth quarter was $0.17, bringing full year adjusted EPS to $0.41. The warrant takeout during the second quarter along with the founder share vestings in the fourth quarter affected EPS by just $0.01 for the full year. Now moving to the Nuclear and Safety group on slide seven, fourth quarter segment revenue increased 13.2% to $168.8 million. Organic growth in the fourth quarter was 13.9%. That organic growth showed sustained strength from our nuclear power business, primarily from the French and safety-critical products businesses; this was combined with solid growth across all the other end markets we participate in. Full year Nuclear and Safety group revenue came to $561.1 million, up 8.7% from 2023. Nuclear-related activity from Europe and Korea served as a major driver of annual growth. Full year organic revenue rose 8.8%, surpassing our expectations of mid-single digit plus growth. This segment's two-year organic growth stack comes in at a strong 18.9%. For our Nuclear and Safety division, fourth quarter adjusted EBITDA rose 20%, reaching $52.8 million. Adjusted EBITDA margin likewise widened by roughly 180 basis points, landing at 31.3%. Solid operating leverage, early signals from our procurement efforts, and an improved mix are all coming through in these results. As you may remember, at this point a year ago, we were talking about certain difficulties within our French business. I'm glad to report those are mostly behind us now, since the organizational and process changes the team implemented during 2024 produced the results we were aiming for, and performance in that region has returned to a more normal level. A special thank you goes out to our French colleagues for their tremendous effort in 2024 to achieve solid performance. For the full year, Nuclear and Safety adjusted EBITDA came to $159.8 million, which is 18% above last year. Margins reached 28.5%, an increase of about 230 basis points relative to the prior year. Operating leverage accounted for half of that margin gain, while the remainder stemmed from management's actions on procurement processes that began mid-year along with our heightened emphasis on factory floor initiatives. This served to counterbalance a larger bonus accrual during the fourth quarter in this segment. Slide eight offers further detail on our Medical segment. Fourth quarter revenue for the Medical segment totaled $85.5 million, which is up $4.2 million, or 5.2%, against the fourth quarter of 2023. Organic revenue rose 3.7% during the quarter, powered by our nuclear medicine and dosimetry businesses while being partly offset by our radiation therapy quality assurance, or RTQA, business. Keep in mind, we posted organic growth of nearly 10% in this segment during last year's fourth quarter, so comparisons were difficult, especially within the RTQA business. Medical faced three headwinds during the quarter. Radiation therapy acted as a headwind to organic growth, mainly because of China, which reduced total Medical revenue by about 210 basis points. Our deliberate exit from the lasers business created a 110 basis points headwind, and we encountered a further headwind of roughly 60 basis points from combining our Wisconsin and Virginia businesses during the quarter. It's also worth mentioning that we rolled out a new ERP across this combined business in Q1 2025. Inorganic fourth quarter revenue increased 1.5%, which reflects a partial quarter's contribution from the EC2 acquisition. As a reminder, we completed the EC2 acquisition in November 2023. Full year Medical segment revenue reached $299.7 million, which is 5.3% greater than 2023. The $15.2 million gain over full year 2023 mostly reflects the full year effect of our EC2 acquisition plus growth in our nuclear medicine and dosimetry businesses. Total growth was divided about equally between organic and inorganic, at 2.6% and 2.7%, respectively. For our Medical business, 2024 was a year of resilience. Our China RTQA business finished the year down roughly 40%. Absent that headwind, our Medical group would have delivered organic growth of approximately 5%. When you factor in that we shut down the lasers business, the Medical segment’s organic growth for the year comes out to about 5.5%. Since some of you may not be familiar with the history yet, the lasers product line had been losing money, so exiting it will help results through subtraction rather than addition. Moving on to EBITDA, the Medical group’s adjusted EBITDA for the quarter reached $33.2 million, which is 6.1% higher than the same period a year earlier. Adjusted EBITDA margins rose 30 basis points, reaching 38.8%. For the full year, adjusted EBITDA came to $104.6 million, while margins increased 50 basis points to 34.8%. Within Medical during the fourth quarter, a sizable release from bonus accruals provided a partial offset to operating inefficiencies tied to our move from Wisconsin and Virginia, along with certain unfavorable mix effects. Now let’s shift to orders and backlog, beginning on slide nine. Rather than diving straight into the full-year order picture, let’s first cover our fourth-quarter performance, keeping in mind that we were up against a 30% order growth comparison from the fourth quarter of 2023. Orders for the quarter increased 6% versus the fourth quarter of last year. Once you adjust for currency and M&A, that figure is actually up roughly 6.8%.
Brian Schopfer
executiveWhen you strip out the noise from the new builds this quarter and the fourth quarter of last year, Q4 orders rose about 5%. I know there are a lot of moving pieces there, but even so, it was a solid quarter, and we should also acknowledge that certain items we had hoped to close slipped out of the year. Large orders, as you're aware, have a tendency to be somewhat lumpy in our line of work. That's the point we tried to make with the slide, to shed light on what's really driving orders beneath the surface. For the entire year, if you set aside the sizable orders and that nonrecurring debooking we talked about during Q3, the adjusted order book for 2024 on an underlying basis rose approximately 3%, which demonstrates the strength of the book and bill operation. Slide 10 shows how our backlog has been trending. Q4 backlog totaled $812 million. After accounting for the more robust U.S. dollar in that quarter plus the Turkey debooking referenced above, adjusted backlog was essentially unchanged from the equivalent quarter last year. Tom already mentioned that the orders we're carrying right now give us a line of sight to roughly 49% of the midpoint for our 2025 revenue guidance, which is a better position than we were in a year ago at this time. Now let's turn to the balance sheet and free cash flow, both of which you'll find on Slide 11. As a quick refresher, 2024 was a full year for us. We reduced net leverage by an additional half turn, eliminated the warrants from our capital structure, all three tranches of Founder Shares became fully vested, and we finished a debt refinancing; when 2025 came to a close, net debt to trailing 12 months adjusted EBITDA stood at 2.5 times, which is slightly ahead of the 2.6 leverage target we had communicated during our third quarter earnings call. That works out to nearly two full turns of deleveraging across the last two years. As we laid out at our Investor Day, this aggressive deleveraging has strengthened our financial position and positioned us for more M&A in 2025. M&A runs in our DNA, and right now we're evaluating a number of compelling opportunities. Adjusted free cash flow came to $53 million for the quarter and $65 million for the full year. For the full year, adjusted free cash flow matched guidance. For the entire year, our adjusted free cash flow conversion came in at 32% of adjusted EBITDA. That result is not acceptable to us. We continue to identify opportunities to accelerate and bring forward our free cash flow conversion during 2025, and at the midpoint of our guidance, we are committing to a 50% increase in adjusted free cash flow in 2025. Since adjusted free cash flow is made up of multiple components, let's spend a brief moment on each. To begin, elevated CapEx was a drag on adjusted free cash flow. Starting from the high end of the range we gave at the beginning of the year, our CapEx spending ended up slightly higher than we had expected. The main drivers were our dosimetry badge launch along with ongoing investments in our e-commerce and software platforms. The purpose of these investments is to accelerate adoption and growth. Even though software remains a modest portion of our overall business, within Medical we anticipate double-digit revenue growth in the coming year, and we look forward to sharing our progress with you during the June quarter. In addition, we are committing to cut CapEx by roughly 18% in 2025 compared with 2024. Second, net working capital turned out to be a use of cash rather than the source of cash we had expected. Net working capital operating days did come down by roughly nine days, and inventory declined by about $7 million on an FX adjusted basis. On the other hand, cash taxes came in better by $14 million against initial guidance of $37 million. That said, there's a timing effect on cash taxes between 2024 and 2025 amounting to roughly $6 million that we will ultimately see land in 2025; we made progress, just not as much as we had hoped. Opportunities lie ahead. Looking back at 2024, we hit the targets we set at the beginning and the ones we raised later, marking one more year of record results; that momentum is coming with us into 2025, and our confidence keeps growing in the 2025 guidance we shared at December's Investor Day. On Slide 12, you'll see our 2025 guidance restated, including adjusted EPS of $0.45-$0.50 per share. For adjusted EPS, we're assuming an effective tax rate between 25%-27%, which is a significant drop from 2024. Our model uses cash taxes of roughly $40 million and an average share count of about 227 million shares. Compared with 2024, our share count for 2025 came in higher. The main reasons were the Founder Shares vesting during Q4, along with the warrants being taken out in Q2. Those two items together drag adjusted EPS guidance for 2025 down by $0.05 per share. As a reminder, guidance for adjusted EBITDA is $215-$230 million, with margin of 24.5%-25.5%, and we anticipate adjusted EBITDA margin expanding in each quarter of 2025. For the full year 2025, total revenue growth should land somewhere between 4%-6%, and that figure accounts for a foreign exchange headwind of roughly 190 basis points. Organic revenue growth is projected to come in at 5.5%-7.5%. Looking ahead to 2025, we anticipate that organic growth will accelerate progressively throughout the year, reaching its highest point during the third quarter before settling into a more typical pattern in the fourth quarter. As for adjusted free cash flow, our projection falls somewhere in the range of $85-$110 million. We also expect adjusted free cash flow conversion to land between 39%-48% of adjusted EBITDA, and quarterly performance should keep following a smoother trajectory. That wraps up my remarks, so I'll turn things over to the operator to begin the Q&A session.
Chris Moore
analystMorning, everyone. Appreciate you fitting in a few questions. Morning, Chris. Perhaps I'll simply say hello. Let me pick up right where Brian finished. Regarding the gains in EBITDA margin every quarter — typically, Q3 across the past several years has dipped somewhat, so what we're indicating is that this year's Q3 comes in above Q2. I only want to confirm I caught that right.
Brian Schopfer
executiveYes. What I'm referring to, in fact, is every quarter measured against the same quarter a year earlier, rather than one after another.
Chris Moore
analystUnderstood. Alright, that's reasonable. That clears things up. Understood. Great. With all the shifts happening across the nuclear power sector, what's your thinking on nuclear's share of Mirion's overall revenue down the road?
Tom Logan
executiveSure, Chris, I'll handle that one. What's fascinating is that we observed that during 2024, nuclear accounted for roughly 37% of our overall revenue. Take the midpoint of our guidance and project ahead into 2025, and that figure rises; yet with what is obviously an extremely durable trend when it comes to nuclear power expansion, driven not just by talk about hyperscalers, but by several other important themes as well, I believe there's a growing perception of scarcity value surrounding nuclear exposure, since it isn't an area offering many highly investable opportunities; and so, with that in mind, and also considering that, frankly, valuation multiples have largely converged across MedTech and nuclear power, for us, that simply pushes us to keep taking a highly balanced stance when evaluating both organic growth opportunities and inorganic growth opportunities. Still, I'd say the overall result of all this is that our nuclear exposure keeps rising at its foundation, because, as we've said in our guidance, nuclear power is expanding at upper single digits. It's outpacing the company overall. On top of that, if you looked through, once more, our pipeline of both organic and M&A opportunities, it's full of nuclear power-related items; so I think ultimately, there's a chance for us to push that percentage higher.
Chris Moore
analystUnderstood. That's quite useful. Perhaps one final item from my end. There's been a great deal of discussion regarding the nuclear segment. For Medical in 2025, what would you call the largest uncertainties?
Tom Logan
executiveA few come to mind. As Brian laid out quite plainly, and as we've discussed for some time now, the primary obstacle we encountered in Medical during the prior year came from the Chinese marketplace, where the ongoing remainder of anti-corruption efforts has substantially affected MedTech broadly, and specifically the development of additional radiation therapy clinics. A number of the top OEMs in this area had anticipated a turnaround during the previous year. That turnaround never materialized. That said, what our guidance incorporates — what is built into our outlook for the year — is that China shows no recovery whatsoever. So that represents uncertainty number one: should we actually witness a return to what used to be the norm for growth and RTQA in China, that would represent potential upside. Another notable uncertainty concerns the war in Ukraine. Should a faster resolution emerge — and plainly, I believe negotiations are happening at this very moment across multiple fronts — but should that war reach a resolution sooner in the year, meaning around summer, then a massive requirement exists for something akin to a Marshall Plan-style effort to reconstruct Ukraine, and a portion of that would touch the numerous nuclear power plants throughout that region. So whenever that war concludes, we believe an opportunity will arise for us to contribute to the solution by assisting with Ukraine's rebuilding. Past that, presumably once the conflict is resolved, some route toward normalizing trade between Russia and the U.S. exists. In any scenario, we don't truly expect that to occur during this year, but as that situation gets better, it could potentially unlock a bit more. The last point I'd raise concerns the broader macro landscape, encompassing the interplay of yield curve movements, foreign exchange fluctuations, tariff developments, and so on, all of which could break either direction. Still, I believe we've adopted a stance ranging from neutral to conservative regarding each of those. Should we observe any positive shift on those fronts, clearly that would be beneficial for us.
Chris Moore
analystThat's really useful. I'll get back in the queue. Appreciate it, everyone.
Joe Ritchie
analystMorning, folks. Hi, Joe. Thanks for clearing up the organic orders picture for the fourth quarter — up 7% against a 30% comparison. That's a solid result. Nice way to wrap up the year. My first question, I think, is about this book and bill flow operation, which has been expanding at a pretty consistent pace. Tom, could you give us some color on what the opportunity looks like near term and share a bit more detail on what you're picking up regarding that part of the business?
Tom Logan
executiveAll right. I'll speak in more general terms first, and then I'll ask Brian to come in and sort of round out the picture here. But at its heart, this is the same thing we've been discussing for most of the past 2 years: because the nuclear power-related exposure we carry is tied to the installed base. That accounts for roughly 80% of our nuclear power revenue, and that in turn represents a bit under 40% of our total revenue. There's an important dynamic at work — as that base keeps getting more profitable, it fuels larger capital spending budgets. It fuels larger operating budgets, and that also, especially once we move into outage season in spring and fall, fuels some business with very short order cycles, so I think what last year showed us was ongoing strengthening in that core dynamic, with growth in that general flow business, a lot of it coming from the core health in nuclear, though that isn't the only source. We likewise saw improvement in some parts of our Medical business, most notably in nuclear medicine, where the very character of what we sell there involves shorter order cycle times, and so there too we had a favorable dynamic that helped set the cadence.
Brian Schopfer
executiveYes. I believe that's fine. Yes. What we found particularly encouraging during Q4 is that we observed this across both geographies — in Europe as well as in North America. And I'd say the North American operation was somewhat slower regarding nuclear during the initial six months of the year. So that gives us encouragement, Joe.
Joe Ritchie
analystUnderstood — that’s useful, everyone. Next, I’d like to bring up the EDF news, the $100 billion of tendering tied to new data centers powered by AI. I’m simply interested. Of course, I realize this is an opportunity further out, especially because of the strategic partnership all of you have. In the end, what does that mean for all of you? Also, is there any way to sort of consider a timeline for when you begin to see some orders connected to this?
Tom Logan
executiveYes. I believe this really stems from the remarkable momentum present in that market as a whole, along with a significant, enduring partnership with EDF. The key element, Joe, is once more the strategic agreement we entered into a year ago, through which we essentially serve as the exclusive provider of specific content for the upcoming 1 to 2 dozen EPR reactors that will be constructed within France and also for export purposes. That matters, clearly, when considering long-term expansion potential. Yet similar to the wider trends we discuss regarding the installed base, EDF faced significant difficulties 12 months back due to extensive outages tied to various operational problems they encountered as an organization. They have since bounced back. They keep progressing through that rebound. And I think what this AI arrangement signals broadly is the idea that you will witness ongoing vigor in capital expenditures directed at their installed base exceeding 50 reactors in France, that operational availability will become increasingly vital, the capacity factors will become increasingly vital, that possible uprates will become increasingly vital. And I think every one of those elements will work in our favor, once more, simply because of how strong the ties are that we hold and value with EDF.
Joe Ritchie
analystAlright. Perhaps I could slip in one final question. Tom, you offered a bit of perspective regarding possible factors that might shift things as the year moves along. What I'm wondering about — I don't believe I caught you addressing the situation in the U.S. involving DOGE and, in the end, what that might imply for your defense segment. Any thoughts on that, and how are you all evaluating the spectrum of possible results there?
Tom Logan
executiveAlright, there are two major uncertainties we figured someone would ask about. The first involves tariffs, and we can circle back to that; the second concerns the broader budget picture. From our standpoint, if you examine where government money and revenue actually reach us, it flows mainly through two pathways. One is tied to the DOE, mostly around lab equipment, remediation work, and capital equipment at large locations such as Oak Ridge, Savannah River, and elsewhere. Beyond that — and this is worth flagging — there's also SMR development backed by the DOE. The second pathway is the Department of Defense. That means military funding across many programs we serve, plus some we're hoping to serve down the road. At this moment, all signals suggest that as we watch the incoming energy secretary and the shifts happening at the DOD, our sense is that even with DOGE's push to eliminate waste, fraud, and inefficiency, we don't anticipate that threatening in any manner the fundamental relationships and fundamental forces at play in that space. So at present, we're cautiously optimistic that we'll keep servicing existing contracts and, further, we're hopeful for some upside during the year. Another point worth raising regarding tariffs is that we've scrutinized carefully what our total exposure looks like from a general trade perspective. Keep in mind that roughly half our commercial sales happen beyond the U.S.; however, when you account for the offset, in effect the natural hedging between what we produce and what we sell commercially, it's quite robust. A very solid natural equilibrium exists there. Consequently, if you consider where we anticipate the largest bilateral tariff exposure, those places would be Canada, Mexico, China, and the EU as a whole. Adding all of those together — once more, bilaterally in both directions, meaning the gross figure rather than a net figure — that sum comes to roughly 13% of our total revenue. So the exposure is notably less than one might guess purely from the company's global footprint and global flows; yet, thinking about it further, we're clearly attempting to stay ahead of any possible tariff moves and doing all we can to grasp the rationale, the mechanics, the timing, every one of those elements. At the same time, we're striving to adopt a far broader perspective — it isn't solely about tariffs. It also involves FX; it involves tax disparities, especially around corporate income tax that could grow wider. It involves trade terms and, over the longer haul, our capacity to keep reducing the tariff danger by relocating our supply chain to shrink that gap further. At this moment, there's a massive set of uncertainties surrounding the possible effects of tariffs. Still, I'd suggest that in our opinion, the risk we face is likely smaller than a lot of people would assume, because of how globally distributed this business is.
Joe Ritchie
analystThat's really useful, Tom. Thanks.
Vlad Bystricky
analystGood morning, everyone. I appreciate you fitting me in. Let me kick things off with something that builds on what came before — hey, Brian. Perhaps I can just pick up where Joe left off regarding DOGE, federal spending, and what effects might follow. Clearly, you addressed the nuclear angle, but when it comes to nuclear medicine, could reimbursement issues pose any danger to providers' readiness or capacity to put money into your product offerings?
Tom Logan
executiveRight. That's not our view, Vlad. Regarding nuclear medicine, during the prior year, we discussed how specific CMS reimbursement codes tied to particularly costly diagnostic agents that form part of this broader theranostics push had received approval, and that essentially generates a greater level of incentive as well as momentum across that segment of the business as a whole; therefore, we anticipate that trend will persist. Our expectation is not that the incoming administration will step in and produce any sort of instant, significant effect on the way CMS approaches reimbursement codes in nuclear medicine. That would also hold for radiation therapy, where there is a continuing situation involving the full array of reimbursement codes that is simply inherent to the business. Once more, we foresee no substantial shifts on that front in the coming year that the new administration and/or DOGE would specifically bring about.
Vlad Bystricky
analystThanks, Tom — that's useful. I wanted to return to the $300 million-$400 million pipeline of bigger one-time orders. Can you share any detail on when you expect those to start landing? Is it possible that a large share, or even all, of them get booked before the end of 2025? And when you speak with your customers, what are the main things that have to fall into place before those orders can move ahead?
Tom Logan
executiveSure. Honestly, Vlad, things are pretty much the same as before, aside from what we mentioned during the prior quarter when we made the announcement and gave that background — we said back then that these opportunities would probably mostly be traded across the following five quarters. That's still true today. So really, we've only got one quarter behind us on that. What's different now is that the range of possibilities seems to have expanded when it comes to these big projects — some of them really quite large — and we're putting in a lot of effort on every front. Not a single deal has slipped away from us so far, and we're happy with our position. However, big endeavors—especially sizable nuclear ones—naturally have schedules that are tough to nail down when you're attempting to slot them into a specific quarter. Because of that, we're sticking with what we've said: the bulk of these chances should materialize across the rest of 2025. Based on where we stand right now, our aim is to capture our portion of this group, or more.
Vlad Bystricky
analystThanks for that, Tom. I'll pass it back over to you.
Yuan Zhi
analystTom, Brian, congratulations on a call that's now on the record, and thanks for fielding our questions. If I could, I have 2 questions. To start, I'd like to know the timeline for getting operations going again in Russia and Ukraine after peace returns to that region — what the timeline looks like on the nuclear medicine side, and also on the nuclear power side.
Tom Logan
executiveOur perspective on that, Yuan, is that settlement terms in general will clearly be what determines the schedule, and we believe there's a genuine need, especially when it comes to instrumentation tied to nuclear power in both of those markets, Ukraine and Russia. Again, this is hypothetical and all of us are speculating, but we'd assume Ukraine opens up before trade with Russia is normalized. And we stand ready, willing, and able to do anything we can, anything that's needed, not just to assist in bolstering the nuclear infrastructure that already exists, but we also anticipate that once the conflict is resolved, there will be considerable new build activity, really defined by Western reactors in Ukraine. And naturally, we're hoping to take part in that too.
Yuan Zhi
analystRight. Understood. Regarding your second question, it concerns regulatory developments within the United States. I'm interested to know what you're picking up from your customers. Take, for instance, the fact that a new DOE secretary has taken office; also, we have states like Texas and Arizona that are receptive to nuclear power. There's certain legislation and initiatives happening at the state level. I'd simply like to hear what you're picking up from customers.
Brian Schopfer
executiveRight. I mean, the thing we keep picking up on is enthusiasm — and again, if you simply take in the sheer flood of press releases, and we only went through a handful of examples earlier today, the positive news on the nuclear front, in this case particularly within the U.S., over the past 12 months has simply been remarkable. What's genuinely new is the talk about possibly bringing the V.C. Summer Plant back, which we referenced in our prepared remarks — that's a Westinghouse AP1000 unit with two reactors. Obviously that would be terrific, very much in nuclear's favor. Down in Texas, Governor Abbott has made it plain he wants his state to sit at the center of an American nuclear renaissance, one defined by building a genuinely supportive climate for developing and expanding SMR applications, and past that, utility scale too. Our take is that further positive developments will come; we anticipate the Duane Arnold Power Plant in Iowa getting restarted at some point, much like Three Mile Island. And we anticipate the regulatory backdrop being strongly pro-nuclear. A key point: the person coming in as energy secretary is fundamentally an energy man, with a solid oil and gas track record, yet he also serves on the board of Oklo — the Sam Altman SMR venture — so clearly he understands nuclear power deeply. You can reasonably conclude that's a pro-nuclear stance; therefore, at the federal level and at the state level alike, we foresee ongoing backing. The truly central question, I'd say, is where the NRC and other regulators stand — specifically, how much further they move in the direction of simplifying rules, especially for new designs and new builds, so that we might shave years off the schedule and genuinely speed up what the administration and we ourselves hope for: an American nuclear renaissance.
Yuan Zhi
analystYeah, understood. That's quite useful.
Shubham Srivastava
analystGood morning, everyone. This is Shubham, on behalf of Rob. I just wanted to ask about the 2025 guidance you laid out, which includes 80 to 200 basis points of adjusted EBITDA margin expansion. Could you give us some detail on the sources of that improvement? Does it come from gross margin, OpEx leverage, or are there specific areas of the business that will be fueling it?
Brian Schopfer
executiveYeah. Well, I'd say it lines up with what we discussed at our Investor Day. Operating leverage remains our closest ally; we're confident that all the efforts we've made in procurement will keep flowing through and be visible. The Wisconsin-Virginia relocation will definitely start appearing in the P&L; so I'd call it a solid combination of operating leverage, procurement, and various self-help initiatives, such as what we're accomplishing on the factory floor. From a modeling standpoint, I'd say we're assuming somewhat greater margin expansion in Medical than in the nuclear and safety segment; but just as we did this year, we're fairly bullish about what we consider the art of the possible in nuclear safety; so I'd describe it as broad-based, and it aligns with our December discussions.
Shubham Srivastava
analystUnderstood. Understood. All right. I believe we have time for one more. It would be great if you could discuss any initial momentum from the Siemens Healthineers partnership and explain how you've incorporated that into your guidance.
Tom Logan
executiveSure. So as everyone knows, we're still in the very early stages of this strategic alliance, and for those listening, a quick reminder: what this agreement does is take more of our offerings — especially SunCHECK, our top-tier workflow and data management software for RTQA, which stands for radiation therapy quality assurance — and place it into Siemens Healthineers' price book. In practice, that means their worldwide sales organization is now promoting it as the preferred core RTQA software platform. This is essentially a fresh arrangement. We've been collaborating extremely closely with Healthineers to educate their salespeople and to genuinely build up momentum. That said, let me be clear: for this year, we've baked in virtually no additional traction from it. Should we end up seeing substantial commercial momentum from this partnership — the strategic alliance — we'd consider that upside.
Brian Schopfer
executiveRight, and I'd just point out that in my remarks, we mentioned growth in the double digits on the software side, specifically within Medical; so that serves as a solid sort of baseline assumption for the business. Whatever Tom just described would add on top of that.
Shubham Srivastava
analystUnderstood. Understood. All right, that's useful. I'll pass it back over.
Tom Logan
executiveTo wrap up today, I want once more to express gratitude to the Mirion team for a record-setting year. I'm just incredibly, incredibly proud of what was accomplished this year, and of the momentum that so many of my colleagues have built to propel us through 2025 and past it; those shared efforts genuinely form the pulse of this organization. To everyone joining the call today, thank you for being here; in my opinion, we are positioned very well to succeed. Our foundation is solid. Market dynamics remain compelling. We believe 2025 is on track to be yet another year of growth and ongoing performance evolution within the business. I genuinely think the market increasingly grasps what makes our company distinctive. Once again, the reality that we stand alone as a pure play focused on detecting, measuring, and analyzing ionizing radiation — a Category of One, as we enjoy saying — combined with the vertical market exposure we possess and, really, the appealing diversification advantages that come with it, makes us, in my view, a truly fascinating company to keep an eye on. The detail we shared at our Investor Day in December is genuinely driving the story, and I'm eager to keep the conversation going with many of you as the year moves along. So, thank you for your attention today, and we look forward to talking with you next quarter. Good day.
Operator
operatorThanks. That brings today's call to a close. At this point you're free to hang up, and we appreciate your joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mirion Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Mirion Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Mirion Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.